Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Luschin-Ebengreuth Gero |

** = Publications listed in SCI/SSCI/Pubmed

2021

Full paper/article (Journal)

** Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R, , Austrian, Breast, and, Colorectal, Cancer, Study, Group Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med. 2021; 385(5):395-405 Doi: 10.1056/NEJMoa2104162
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Radivojev, S; Luschin-Ebengreuth, G; Pinto, JT; Paudel, A; Frohlich, E THE RELEVANCE OF SIMULATED LUNG FLUID COMPOSITION ON THE DRUG SOLUBILITY AND PREDICTED IN-VIVO PERFORMANCE OF INHALED DRUG DELIVERY
J AEROSOL MED PULM D. 2021; 34(3):A11-A11. [Poster]
Web of Science

 

2015

Full paper/article (Journal)

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol. 2015; 26(2):313-320 Doi: 10.1093/annonc/mdu544 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Full paper/article (Journal)

** Luschin, G; Habersack, M Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey.
Health Commun. 2014; 29(4):421-426 Doi: 10.1080/10410236.2012.743096
Web of Science PubMed FullText FullText_MUG

 

** Rugani, P; Luschin, G; Jakse, N; Kirnbauer, B; Lang, U; Acham, S Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
Clin Oral Investig. 2014; 18(2):401-407 Doi: 10.1007/s00784-013-1012-5
Web of Science PubMed FullText FullText_MUG

 

2013

Full paper/article (Journal)

** Cserni, G; Bori, R; Maráz, R; Leidenius, MH; Meretoja, TJ; Heikkila, PS; Regitnig, P; Luschin-Ebengreuth, G; Zgajnar, J; Perhavec, A; Gazic, B; Lázár, G; Takács, T; Vörös, A; Audisio, RA Multi-institutional comparison of non-sentinel lymph node predictive tools in breast cancer patients with high predicted risk of further axillary metastasis.
PATHOL ONCOL RES. 2013; 19(1): 95-101. Doi: 10.1007/s12253-012-9553-5
Web of Science PubMed FullText FullText_MUG

 

** Habersack, M; Luschin, G Insecurities of women regarding breast cancer research: a qualitative study.
PLoS One. 2013; 8(12):e81770-e81770 Doi: 10.1371/journal.pone.0081770 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Habersack, M; Luschin, G WHO-definition of health must be enforced by national law: a debate.
BMC Med Ethics. 2013; 14(2):24-24 Doi: 10.1186/1472-6939-14-24 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Meretoja, TJ; Audisio, RA; Heikkilä, PS; Bori, R; Sejben, I; Regitnig, P; Luschin-Ebengreuth, G; Zgajnar, J; Perhavec, A; Gazic, B; Lázár, G; Takács, T; Kővári, B; Saidan, ZA; Nadeem, RM; Castellano, I; Sapino, A; Bianchi, S; Vezzosi, V; Barranger, E; Lousquy, R; Arisio, R; Foschini, MP; Imoto, S; Kamma, H; Tvedskov, TF; Jensen, MB; Cserni, G; Leidenius, MH International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.
Breast Cancer Res Treat. 2013; 138(3):817-827 Doi: 10.1007/s10549-013-2468-3
Web of Science PubMed FullText FullText_MUG

 

2012

Full paper/article (Journal)

** Cserni, G; Boross, G; Marz, R; Leidenius, MH; Meretoja, TJ; Heikkila, PS; Regitnig, P; Luschin-Ebengreuth, G; Zgajnar, J; Perhavec, A; Gazic, B; Lzr, G; Takcs, T; Vörös, A; Audisio, RA Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer.
Surg Oncol. 2012; 21(2):59-65 Doi: 10.1016/j.suronc.2011.12.001
Web of Science PubMed FullText FullText_MUG

 

** Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2012; 30(7):722-728 Doi: 10.1200/JCO.2011.36.8993 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Luschin, G; Habersack, M; Gerlich, IA Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate.
BMC MED RES METHODOL. 2012; 12(5): 25-25. Doi: 10.1186/1471-2288-12-25 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Meretoja, TJ; Leidenius, MH; Heikkilä, PS; Boross, G; Sejben, I; Regitnig, P; Luschin-Ebengreuth, G; Žgajnar, J; Perhavec, A; Gazic, B; Lázár, G; Takács, T; Vörös, A; Saidan, ZA; Nadeem, RM; Castellano, I; Sapino, A; Bianchi, S; Vezzosi, V; Barranger, E; Lousquy, R; Arisio, R; Foschini, MP; Imoto, S; Kamma, H; Tvedskov, TF; Kroman, N; Jensen, MB; Audisio, RA; Cserni, G International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer.
J Natl Cancer Inst. 2012; 104(24):1888-1896 Doi: 10.1093/jnci/djs455 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Full paper/article (Journal)

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Pristauz, G; Bauernhofer, T; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Hochreiner, G; Forsthuber, EP; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol. 2011; 12(7):631-641 Doi: 10.1016/S1470-2045(11)70122-X
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Steger, G; Jakesz, R; Singer, C; Dubsky, P; Greil, R Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment
BREAST. 2011; 20: S69-S69.St. Gallen . Doi: 10.1016/S0960-9776(11)70228-4 [Poster]
Web of Science FullText FullText_MUG

 

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Steger, G; Jakesz, R; Singer, C; Eidtmann, H; Greil, R 62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer
BONE. 2011; 48(1):S17-S17. Doi: 10.1016/j.bone.2010.10.045 [Oral Communication]
Web of Science FullText FullText_MUG

 

2010

Short report/Letter

** Eder, M; Bjelic-Radisic, V; Luschin-Ebengreuth, G; Lang, U Vaginal laceration in a premenarcheal girl after sliding down a water chute.
Eur J Obstet Gynecol Reprod Biol. 2010; 150(1):103-104 Doi: 10.1016/j.ejogrb.2009.12.016 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Steger, GG; Jakesz, R; Singer, CF; Eidtmann, H; Greil, R ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
ANN ONCOL. 2010; 21: 79-79.
Web of Science

 

** Rugani, P; Acham, S; Truschnegg, A; Obermayer-Pietsch, B; Jakse, N; Luschin-Ebengreuth, G Prevalence of osteonecrosis of the jaws after a 3-years intravenous bisphosphonate therapy in patients with breast carcinoma
ORAL DIS. 2010; 16(6): 552-552. [Poster]
Web of Science

 

2009

Full paper/article (Journal)

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Pöstlberger, S; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Bjelic-Radisic, V; Samonigg, H; Tausch, C; Eidtmann, H; Steger, G; Kwasny, W; Dubsky, P; Fridrik, M; Fitzal, F; Stierer, M; Rücklinger, E; Greil, R; ABCSG-12 Trial Investigators; Marth, C Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
N Engl J Med. 2009; 360(7):679-691 Doi: 10.1056/NEJMoa0806285 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Wehrschuetz, M; Schöllnast, H; Wehrschuetz, E; Renner, W; Luschin, G VEGF 936C > T Polymorphism and Association of BI-RADS Score in Women with Suspected Breast Cancer.
Breast Cancer (Auckl). 2009; 3(3):77-81 Doi: 10.4137/BCBCR.S3164 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Journal)

** Bjelic-Radisic, V; Trattner, E; Luschin-Ebengreuth, G; Pristauz-Telsnigg, G; Kapp, K Long-term follow up of breast cancer patients with bone metastasis
GEBURTSH FRAUENHEILK. 2009; 69(5):P124-
Web of Science

 

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Poestlberger, S; Menzel, C; Jakesz, R; Kubista, E; Marth, C; Greil, R ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL
ANN ONCOL. 2009; 20: 30-30.-IMPAKT Breast Cancer Conference; MAY 7-9, 2009; Brussels, BELGIUM. [Poster]
Web of Science

 

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial
CANCER RES. 2009; 69(2):191S-191S.-31st Annual San Antonio Breast Cancer Symposium; DEC 10-14, 2008; San Antonio, TX. [Oral Communication]
Web of Science

 

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial
BREAST. 2009; 18: S59-S59. Doi: 10.1016/S0960-9776(09)70187-0
Web of Science FullText FullText_MUG

 

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL
ANN ONCOL. 2009; 20: 30-30.
Web of Science

 

** Jakesz, R; Gnant, M; Griel, R; Tausch, C; Samonigg, H; Kwasny, W; Kubista, E; Stierer, M; Luschin, G; Ruecklinger, E; Mittlbock, M Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8
CANCER RES. 2009; 69(2):67S-67S.-31st Annual San Antonio Breast Cancer Symposium; DEC 10-14, 2008; San Antonio, TX. [Keynote lecture]
Web of Science

 

2008

Full paper/article (Journal)

** Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kässmann, H; Piswanger-Sölkner, JC; Seifert, M; Ploner, F; Menzel, C; Dubsky, P; Fitzal, F; Bjelic-Radisic, V; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Wohlmuth, P; Mittlböck, M; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group (ABCSG) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Lancet Oncol. 2008; 9(9):840-849 Doi: 10.1016/S1470-2045(08)70204-3
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Mlineritsch, B; Tausch, C; Singer, C; Luschin-Ebengreuth, G; Jakesz, R; Ploner, F; Stierer, M; Melbinger, E; Menzel, C; Urbania, A; Fridrik, M; Steger, G; Wohlmuth, P; Gnant, M; Greil, R; on behalf of the Austrian Breast, Colorectal Cancer Study Group (ABCSG) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Breast Cancer Res Treat. 2008; 112(1): 203-213. Doi: 10.1007/s10549-007-9843-x
Web of Science PubMed FullText FullText_MUG

 

** Moinfar, F; Beham, A; Friedrich, G; Deutsch, A; Hrzenjak, A; Luschin, G; Tavassoli, FA Macro-environment of breast carcinoma: frequent genetic alterations in the normal appearing skins of patients with breast cancer.
Mod Pathol. 2008; 21(5):639-646 Doi: 10.1038/modpathol.2008.28 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12
ANN ONCOL. 2008; 19: 44-44.-33rd European-Society-for-Medical-Oncology Congress; SEP 12-16, 2008; Stockholm, SWEDEN. [Keynote lecture]
Web of Science

 

** Luschin-Ebengreuth, G; Bjelic, V; Pristauz, G Paradigm change with mamma carcinoma - Adequate local treatment with stage IV
GEBURTSH FRAUENHEILK. 2008; 68(4):433-433.
Web of Science

 

2007

Full paper/article (Journal)

** Gnant, MF; Mlineritsch, B; Luschin-Ebengreuth, G; Grampp, S; Kaessmann, H; Schmid, M; Menzel, C; Piswanger-Soelkner, JC; Galid, A; Mittlboeck, M; Hausmaninger, H; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2007; 25(7): 820-828. Doi: 10.1200/JCO.2005.02.7102 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Pötter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, L; Pakisch, B; Taucher, S; Hammer, J; Luschin-Ebengreuth, G; Schmid, M; Sedlmayer, F; Stierer, M; Reiner, G; Kapp, K; Hofbauer, F; Rottenfusser, A; Pöstlberger, S; Haider, K; Draxler, W; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
INT J RADIAT ONCOL BIOL PHYS. 2007; 68(2): 334-340. Doi: 10.1016/j.ijrobp.2006.12.045
Web of Science PubMed FullText FullText_MUG

 

** Steger, GG; Galid, A; Gnant, M; Mlineritsch, B; Lang, A; Tausch, C; Rudas, M; Greil, R; Wenzel, C; Singer, CF; Haid, A; Postlberger, S; Samonigg, H; Luschin-Ebengreuth, G; Kwasny, W; Klug, E; Kubista, E; Menzel, C; Jakesz, R Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
J Clin Oncol. 2007; 25(15):2012-2018 Doi: 10.1200/JCO.2006.09.1777 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Abstract (Journal)

** Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kaessmann, H; Piswanger-Soelkner, C; Seifert, M; Schippinger, W; Menzel, C; Dubsky, P; Fitzal, F; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Jakesz, R Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12
BREAST CANCER RES TREAT. 2007; 106: S8-S8. [Oral Communication]
Web of Science

 

2006

Abstract (Journal)

** Potter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, L; Pakisch, B; Taucher, S; Hammer, J; Luschin-Ebengreuth, G; Schmid, M; Sedlmayer, F; Stierer, M; Reiner, G; Hackl, A; Hofbauer, F; Rottenfusser, A; Haider, K; Draxler, W; Jakesz, R Lumpectomy plus tamoxifen or anastrazole with or without whole breast irradiation in women with favourable early breast cancer
STRAHLENTHER ONKOL. 2006; 182: 25-25. [Poster]
Web of Science

 

2005

Abstract (Journal)

** Gnant, MFX; Poetter, R; Kwasny, W; Tausch, C; Handl-Zeller, E; Pakesch, B; Schmid, M; Hausmaninger, H; Stierer, M; Kubista, E; Sedlmayer, F; Draxler, W; Luschin-Ebengreuth, G; Jakesz, R Breast conservation without radiotherapy in low risk breast cancer patients - results of 2 prospective clinical trials of the Austrian Breast and Colorectal Cancer Study Group involving 1,518 postmenopausal patients with endocrine responsive breast cancer
BREAST CANCER RES TREAT 2005 94: -.
Web of Science

 

** Jakesz, R; Gnant, M; Greil, R; Tausch, C; Samonigg, H; Kwasny, W; Kubista, E; Stierer, M; Luschin, G; Mittlboeck, M The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
BREAST CANCER RES TREAT. 2005; 94: S10-S10.
Web of Science

 

** Poetter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, E; Hammer, J; Luschin-Ebengreuth, G; Schmid, M; Stierer, M; Jakesz, R Lumpectomy plus tamoxifen or arimidex with or without whole breast irradiation in women with favourable early breast cancer
EJC SUPPL. 2005; 3(2): 75-75.
Web of Science

 

** Poetter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, L; Hammer, J; Pakisch, B; Luschin-Ebengreuth, G; Schmid, M; Stierer, M; Draxler, W; Jakesz, R Lumpectomy plus tamoxifen or arimidex with or without whole breast irradiation in women with favorable early breast cancer
INT J RADIAT ONCOL BIOL PHYS 2005 63: S2-S2. Doi: 10.1016/j.ijrobp.2005.07.009
Web of Science FullText FullText_MUG

 

2004

Abstract (Journal)

** Gnant, M; Jakesz, R; Mlineritsch, B; Luschin-Ebengreuth, G; Schmid, M; Menzel, C; Kubista, E; Samonigg, H; Hausmaninger, H Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12)
BREAST CANCER RES TREAT. 2004; 88: S8-S9.
Web of Science

 

2002

Full paper/article (Journal)

** Regitnig, P; Moser, R; Thalhammer, M; Luschin-Ebengreuth, G; Ploner, F; Papadi, H; Tsybrovskyy, O; Lax, SF Microsatellite analysis of breast carcinoma and corresponding local recurrences.
J Pathol. 2002; 198(2):190-197 Doi: 10.1002/path.1193
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Gnant, M; Hausmaninger, H; Samonigg, H; Mlineritsch, B; Taucher, S; Luschin-Ebengreuth, G; Jakesz, R Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+/- zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial.
BREAST CANCER RES TREAT. 2002; 76: S31-S31.
Web of Science

 

1998

Full paper/article (Journal)

** Kurschel, S; Petru, E; Luschin, G; Pickel, H High-Risk Metastatic Choriocarcinoma - Are 2 Additional Chemotherapy Courses After a Complete Beta-hCG-Titer Remission Sufficient - A Case-Report
GEBURTSH FRAUENHEILK 1998 58: 51-53. Doi: 10.1055/s-2007-1022120
Web of Science FullText FullText_MUG

 

1997

Full paper/article (Journal)

** Luschinebengreuth, G; Petru, E; Mayer, R Long-Term Remission of a Single Brain Metastasis Induced by Radiotherapy and 2nd-Line Emaco Chemotherapy - Case-Report
GEBURTSH FRAUENHEILK 1997 57: 477-478. Doi: 10.1055/s-2007-1023121 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Abstract (Journal)

** Hartwagner, K; Schmidt, F; LuschinEbengreuth, G; Groll, R Diagnostic value of US guided fine needle aspiration cytology in breast lesions
BREAST 1997 6: P907-P907.
Web of Science

 

1996

Full paper/article (Journal)

** Preidler, KW; Luschin, G; Tamussino, K; Szolar, DM; Stiskal, M; Ebner, F Magnetic resonance imaging in patients with gestational trophoblastic disease.
Invest Radiol. 1996; 31(8):492-496 Doi: 10.1097%2F00004424-199608000-00004
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1993

Full paper/article (Journal)

** Luschinebengreuth, G; Petru, E; Pickel, H Chemotherapy in Trophoblastic Tumors
ARCH GYNECOL OBSTET. 1993; 254: 1113-1115. Doi: 10.1007/BF02266331
Web of Science FullText FullText_MUG

 

Review

** Petru, E; Lahousen, M; Urdl, W; Luschin, G; Pickel, H Hormone substitution in patients after primary treatment of gynecologic malignancies
Wien Med Wochenschr. 1993; 143(21): 539-541.
PubMed

 

1991

Full paper/article (Journal)

** Luschin-Ebengreuth, G; Girardi, F; Haas, J Cervix cancers in young women
Gynakol Rundsch. 1991; 31 Suppl 2(10): 241-243. Doi: 10.1159/000271750
PubMed FullText FullText_MUG

 

** Luschinebengreuth, G; Klein, GE; Schreyer, H; Lahousen, M Embolization of Vitally Bleeding Tumor Vessels in Gynecological Tumors
ARCH GYNECOL OBSTET. 1991; 250: 289-290. Doi: 10.1007/978-3-642-76124-9_166
Web of Science FullText FullText_MUG

 

1989

Full paper/article (Journal)

** Luschin-Ebengreuth, G; Scharnagl, E A case of macromastia in pregnancy
Gynakol Rundsch. 1989; 29 Suppl 2(6): 335-337. Doi: 10.1159/000271103 (- Case Report)
PubMed FullText FullText_MUG

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint